Thank you for choosing Halwel.
You're a few minutes from a real clinical evaluation. Here's what to expect — and a little of the science behind why GLP-1 care is about more than a number on the scale.
~10 minutes · private · pause anytime
A few things to know
About 10 minutes, at your pace
A few short sections on your goals, health history, and medications. Pause anytime — we save your place.
Private and protected
Your answers are encrypted and HIPAA-protected, shared only with your care team.
A clinician reviews everything
This isn't automated. A licensed provider evaluates your history and decides what's safe and right for you.
research-backed
More than weight loss
The science on GLP-1s reaches further than most people know.
Better sleep, not just smaller jeans
In 2024, a GLP-1 became the first medication ever FDA-approved for obstructive sleep apnea — cutting breathing interruptions by ~20–25 an hour in trials.
Studied in adults with obesity-related sleep apnea; benefit is tied to weight loss.
U.S. FDA approval announcement, 2024 ↗Protection that reaches your heart
In a 17,600-person trial, semaglutide reduced major cardiovascular events — heart attack and stroke — by 20%, and lowered the risk of death.
Shown in a high-risk cardiovascular population, in clinical trials — not a guarantee of individual results.
The SELECT trial, New England Journal of Medicine, 2023 ↗A quieter mind around food
Many people describe GLP-1s turning down “food noise” — the constant, intrusive thoughts about eating — by acting on the brain's reward pathways.
Widely reported by patients and supported by mechanism studies; experiences vary.
Scientific American — the science of “food noise” ↗GLP-1s are prescription medications with risks and side effects, and many of these benefits are linked to the weight loss itself. A clinician will review whether treatment is appropriate for you.